Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2017) 49 EP180 | DOI: 10.1530/endoabs.49.EP180

1Department of Endocrinology, Hospital Universitario de La Princesa, Madrid, Spain; 2Instituto de Investigación Princesa, Madrid, Spain; 3Department of Surgery, Hospital Universitario de La Princesa, Madrid, Spain.


Introduction: One of the main difficulties in the study of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) is their wide heterogeneity and variable outcome. Several potential influencing factors on patient survival have been recently identified. These factors could help predict patients’ prognosis.

Objectives: Analysis of long-term survival of our GEP-NETs cohort according to the presence of metastatic disease, tumor grade, age, sex, tumor functionality and tumor origin.

Materials and methods: Ambispective study of patients with GEP-NETs in Hospital Universitario La Princesa (Madrid, Spain) from 1995 to the present. Survival analysis and factors involved were assessed by Kaplan-Meier method and Cox regression analysis using STATA v12.0.

Results: One hundred and four patients were evaluated (55 women, age 61±16 years). Primary origin was pancreatic in 39, intestinal in 69 and unknown in 6 cases. Histological tumor grade was G1 in 51%, G2 in 39% and G3 in 10% of cases. 68% patients had metastatic disease and 33 died during follow-up. Median survival time was 5261 days (CI 3247 to not reached). Grade G3 multiplied the risk of mortality by 26 (CI 6 – 112); metastatic disease doubled the risk (CI 1.3 – 5.1); every 10-year increase in age multiplied the risk by 1.6 (CI 1.2 – 2.2); and if the tumor had unknown primary origin, the risk was multiplied by 2.5 (IC 0.9 – 7.4). Sex and tumor functionality did not significantly affect survival.

Conclusions: Several factors influence the heterogeneity and clinical outcome of patients with NETs. Median survival is reduced in patients with G3, metastasis, and primary tumors of unknown origin. Knowing these factors guides the therapeutic approach of this rare disease.

Volume 49

19th European Congress of Endocrinology

Lisbon, Portugal
20 May 2017 - 23 May 2017

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.